Semaphorin 4A as a Potential Biomarker for Diagnosis of Systemic Lupus Erythematosus

References

• Arbitman L, Furie R, Vashistha H. 2022. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun. 10:102873.
   Google Scholar
• Aringer M. 2019. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 49:S14–17.
   PubMed Web of Science ®Google Scholar
• Aringer M, Petri M. 2020. New classification criteria for systemic lupus erythematosus. Curr Opin Rheumatol. 32(6):590–96.
   PubMed Web of Science ®Google Scholar
• Bejar J, Kessler O, Sabag AD, Sabo E, Itzhak OB, Neufeld G, Vadasz Z. 2018. Semaphorin3a-A potential therapeutic tool for lupus nephritis. Front Immunol. 4:634.
   Google Scholar
• Bernardoff I, Picq A, Loiseau P, Foret T, Dufrost V, Moulinet T, Unlu O, Erkan D, Wahl D, Zuily S. 2022. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 21(1):102913.
   PubMed Web of Science ®Google Scholar
• Carvalheiro T, Affandi AJ, Malvar-Fernández B, Dullemond I, Cossu M, Ottria A, Mertens JS, Giovannone B, Bonte-Mineur F, Kok MR, et al. 2019. Induction of inflammation and fibrosis by semaphorin 4A in systemic sclerosis. Arthritis Rheumatol. 71:1711–22.
   PubMedGoogle Scholar
• Cavalcanti CAJ, Germoglio V, de Azevêdo Silva J, Glesse N, Vianna P, Cechim G, Monticielo OA, Xavier RM, Brenol JCT, Brenol CV, et al. 2019. T-cell specific upregulation of Sema4A as risk factor for autoimmunity in systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity. 53:1–6.
   PubMed Web of Science ®Google Scholar
• Farda D, Tamagnone L. 2021. Semaphorins in health and disease. Cytokine Growth Factor Rev. 57:55–63.
   PubMed Web of Science ®Google Scholar
• Feng Y, Yang M, Wu H, Lu Q. 2020. The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity. 53(2):56–64.
   PubMed Web of Science ®Google Scholar
• Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, Homer R, Gulati M, Siner J, Elias J, et al. 2011. Role of Semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum. 63:2484–94.
   PubMedGoogle Scholar
• Gao H, Ma X, Guo Q, Zou, YD, Zhong, YC, Xie, LF, Shao, M, Zhang, XW. 2017. Expression and clinical significance of Semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus. Zhong Hua Yi Xue Za Zhi. 97:370–74.
   PubMedGoogle Scholar
• Justiz Vaillant AA, Goyal A, Varacallo M. 2022. Systemic lupus erythematosus. In StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC. 1–16.
   Google Scholar
• Kay J, Upchurch KS. 2012. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 51:5–9.
   PubMedGoogle Scholar
• Kumanogoh A, Shikina T, Suzuki K, Uematsu S, Yukawa K, Kashiwamura S-I, Tsutsui H, Yamamoto M, Takamatsu H, Ko-Mitamura EP, et al. 2005. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A‑ deficient mice. Immunity. 22:305–16.
   PubMed Web of Science ®Google Scholar
• Lazar S, Kahlenberg JM. 2022. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med. 8:2.1–2.14.
   Google Scholar
• Lu N, Li Y, Zhang Z, Xing J, Sun Y, Yao S, Chen L. 2018. Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4. Nat Commun. 9(1):742.
   PubMedGoogle Scholar
• Migliorini P, Baldini C, Rocchi V, Bombardieri S. 2005. Anti-Sm and anti-RNP antibodies. Autoimmunity. 38(1):47–54.
   PubMed Web of Science ®Google Scholar
• Nakatsuji Y, Okuno T, Moriya M, Sugimoto T, Kinoshita M, Takamatsu H, Nojima S, Kimura T, Kang S, Ito D, et al. 2012. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol. 188:4858–65.
   PubMed Web of Science ®Google Scholar
• Nishide M, Kumanogoh A. 2018. The role of semaphorins in immune responses and autoimmune rheumatic diseases. Nat Rev Rheumatol. 14:19–31.
   PubMed Web of Science ®Google Scholar
• Peng HY, Gao W, Chong FR, Liu H-Y, Zhang J. 2015. Semaphorin 4A enhances lung fibrosis through activation of Akt via PlexinD1 receptor. J Biosci. 40:855–62.
   PubMed Web of Science ®Google Scholar
• Rimar D, Nov Y, Rosner I, Slobodin G, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Boulman N, et al. 2015. Semaphorin 3A an immunoregulator in systemic sclerosis. Rheumatol Int. 35:1625–30.
   PubMed Web of Science ®Google Scholar
• Sandrin-Garcia P, Junta CM, Fachin AL, Mello SS, Baião AMT, Rassi DM, Ferreira MCT, Trevisan GL, Sakamoto-Hojo ET, Louzada-Júnior P, et al. 2009. Shared and unique gene expression in systemic lupus erythematosus depending on disease activity. Ann NY Acad Sci. 1173:493–500.
   PubMed Web of Science ®Google Scholar
• Urhan E, Camci Urhan A, Okan Dogan H, Sahin A. 2022. Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren’s syndrome. Rheumatol Int. 28. doi:10.1007/s00296-022-05197-y
   Web of Science ®Google Scholar
• Vadasz Z, Goldeberg Y, Halasz K, Rosner I, Valesini G, Conti F, Perricone C, Sthoeger Z, Bezalel SR, Tzioufas AG, et al. 2016. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clin Immunol. 3:114–18.
   Google Scholar
• Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H. 2001. Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood. 97(11):3498–504.
   PubMed Web of Science ®Google Scholar
• Wang P, Mao YM, Liu LN, Zhao C-N, Li X-M, Pan H-F. 2019. Decreased Expression of Semaphorin 3A and Semaphorin 7A levels and its association with systemic lupus erythematosus. Immunol Invest. 15:1–12.
   Google Scholar
• Wang L, Song G, Zheng Y, Tan W, Pan J, Zhao Y, Chang X. 2015. Expression of Semaphorin 4A and its potential role in rheumatoid arthritis. Arthritis Res Ther. 25(1):227.
   Google Scholar
• Xie J, Wang H. 2017. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res Ther. 19:10.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Z, Wang W. 2020. Semaphorin 4D induces an Imbalance of Th17/Treg cells by activating the aryl hydrocarbon receptor in ankylosing spondylitis. Front Immunol. 8:2151.
   Google Scholar
• Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S, Kimura T, Ito D, Morimoto K, Nishide M, et al. 2015. Semaphorin 4D contributes to rheumatoid arthritis by inducing inflammatory cytokine production: pathogenic and therapeutic implications. Arthritis Rheumatol. 67:1481–90.
   PubMed Web of Science ®Google Scholar